Cargando…

Effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial

OBJECTIVES: This study was designed to measure the beneficial effects of a combination of nutraceutics (NUT; AkP04, Morestril(®), Akademy Pharma) containing soy isoflavones (80 mg), dry extract of Angelica sinensis (50 mg), dry extract of Morus alba leaf (200 mg) and magnesium (56.25 mg) in the reli...

Descripción completa

Detalles Bibliográficos
Autores principales: Trimarco, Valentina, Rozza, Francesco, Izzo, Raffaele, De Leo, Vincenzo, Cappelli, Valentina, Riccardi, Carla, Di Carlo, Costantino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066860/
https://www.ncbi.nlm.nih.gov/pubmed/27785106
http://dx.doi.org/10.2147/IJWH.S115948
_version_ 1782460554216996864
author Trimarco, Valentina
Rozza, Francesco
Izzo, Raffaele
De Leo, Vincenzo
Cappelli, Valentina
Riccardi, Carla
Di Carlo, Costantino
author_facet Trimarco, Valentina
Rozza, Francesco
Izzo, Raffaele
De Leo, Vincenzo
Cappelli, Valentina
Riccardi, Carla
Di Carlo, Costantino
author_sort Trimarco, Valentina
collection PubMed
description OBJECTIVES: This study was designed to measure the beneficial effects of a combination of nutraceutics (NUT; AkP04, Morestril(®), Akademy Pharma) containing soy isoflavones (80 mg), dry extract of Angelica sinensis (50 mg), dry extract of Morus alba leaf (200 mg) and magnesium (56.25 mg) in the relief of somatic, psychological, and urogenital symptoms in postmenopausal patients, using the validated Menopause Rating Scale (MRS) and cardiovascular risk factors. MATERIALS AND METHODS: A total of 43 symptomatic postmenopausal women (MRS ≥20) were enrolled in a crossover trial. After a 2-week run-in period, patients were randomized into two arms. One arm received probiotics plus placebo over 4 weeks, followed by a 4-week treatment with probiotics plus NUT. The second arm received probiotics plus NUT for 4 weeks, followed by a 4-week treatment with probiotics plus placebo. RESULTS: After the NUT period, participants showed a significant reduction in MRS score (18.4±5.4) in comparison to baseline (28.4±5) and the placebo period (28±5.2) (P<0.0001 for both comparisons). Furthermore, at the end of the active-treatment period, we observed a significant reduction in triglycerides, total and low-density lipoprotein cholesterol plasma levels and an increase in high-density lipoprotein cholesterol plasma concentration versus baseline and versus placebo (all P<0.04). Moreover, during the NUT period, we detected a significant reduction in diastolic blood pressure in comparison to baseline, but not in comparison to the placebo period. CONCLUSION: This NUT combination was effective for the relief of menopause symptoms in postmenopausal patients and improved their cardiovascular risk profile.
format Online
Article
Text
id pubmed-5066860
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50668602016-10-26 Effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial Trimarco, Valentina Rozza, Francesco Izzo, Raffaele De Leo, Vincenzo Cappelli, Valentina Riccardi, Carla Di Carlo, Costantino Int J Womens Health Original Research OBJECTIVES: This study was designed to measure the beneficial effects of a combination of nutraceutics (NUT; AkP04, Morestril(®), Akademy Pharma) containing soy isoflavones (80 mg), dry extract of Angelica sinensis (50 mg), dry extract of Morus alba leaf (200 mg) and magnesium (56.25 mg) in the relief of somatic, psychological, and urogenital symptoms in postmenopausal patients, using the validated Menopause Rating Scale (MRS) and cardiovascular risk factors. MATERIALS AND METHODS: A total of 43 symptomatic postmenopausal women (MRS ≥20) were enrolled in a crossover trial. After a 2-week run-in period, patients were randomized into two arms. One arm received probiotics plus placebo over 4 weeks, followed by a 4-week treatment with probiotics plus NUT. The second arm received probiotics plus NUT for 4 weeks, followed by a 4-week treatment with probiotics plus placebo. RESULTS: After the NUT period, participants showed a significant reduction in MRS score (18.4±5.4) in comparison to baseline (28.4±5) and the placebo period (28±5.2) (P<0.0001 for both comparisons). Furthermore, at the end of the active-treatment period, we observed a significant reduction in triglycerides, total and low-density lipoprotein cholesterol plasma levels and an increase in high-density lipoprotein cholesterol plasma concentration versus baseline and versus placebo (all P<0.04). Moreover, during the NUT period, we detected a significant reduction in diastolic blood pressure in comparison to baseline, but not in comparison to the placebo period. CONCLUSION: This NUT combination was effective for the relief of menopause symptoms in postmenopausal patients and improved their cardiovascular risk profile. Dove Medical Press 2016-10-11 /pmc/articles/PMC5066860/ /pubmed/27785106 http://dx.doi.org/10.2147/IJWH.S115948 Text en © 2016 Trimarco et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Trimarco, Valentina
Rozza, Francesco
Izzo, Raffaele
De Leo, Vincenzo
Cappelli, Valentina
Riccardi, Carla
Di Carlo, Costantino
Effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial
title Effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial
title_full Effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial
title_fullStr Effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial
title_full_unstemmed Effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial
title_short Effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial
title_sort effects of a new combination of nutraceuticals on postmenopausal symptoms and metabolic profile: a crossover, randomized, double-blind trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066860/
https://www.ncbi.nlm.nih.gov/pubmed/27785106
http://dx.doi.org/10.2147/IJWH.S115948
work_keys_str_mv AT trimarcovalentina effectsofanewcombinationofnutraceuticalsonpostmenopausalsymptomsandmetabolicprofileacrossoverrandomizeddoubleblindtrial
AT rozzafrancesco effectsofanewcombinationofnutraceuticalsonpostmenopausalsymptomsandmetabolicprofileacrossoverrandomizeddoubleblindtrial
AT izzoraffaele effectsofanewcombinationofnutraceuticalsonpostmenopausalsymptomsandmetabolicprofileacrossoverrandomizeddoubleblindtrial
AT deleovincenzo effectsofanewcombinationofnutraceuticalsonpostmenopausalsymptomsandmetabolicprofileacrossoverrandomizeddoubleblindtrial
AT cappellivalentina effectsofanewcombinationofnutraceuticalsonpostmenopausalsymptomsandmetabolicprofileacrossoverrandomizeddoubleblindtrial
AT riccardicarla effectsofanewcombinationofnutraceuticalsonpostmenopausalsymptomsandmetabolicprofileacrossoverrandomizeddoubleblindtrial
AT dicarlocostantino effectsofanewcombinationofnutraceuticalsonpostmenopausalsymptomsandmetabolicprofileacrossoverrandomizeddoubleblindtrial